clinical trial · NCT07895355
Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer
RemeGen Co., Ltd.·phase2·not yet recruiting·n = 412
Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line TherapyRC148 plus Telisotuzumab adizutecanRC148 plus Telisotuzumab adizutecanRC148 plus Telisotuzumab adizutecanRC148 plus Telisotuzumab adizutecanTelisotuzumab adizutecan plus BevacizumabTelisotuzumab adizutecan plus Bevacizumab
brief summary
RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer
started
Nov 1, 2026
primary completion
Jul 1, 2028
completion
Jan 1, 2030
last updated
Oct 26, 2026
official title
A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan With or Without Chemotherapy as a First-Line or Second-Line Therapy for Unresectable Colorectal Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol